linjc16/ctgov huggingface dataset:
Effects of EGCG-Enhanced Extra Virgin Olive Oil on Endothelial Function

Study Overview
=================
Brief Summary
-----------------
This study is being done to determine if the use of EGCG-Enhanced Extra Virgin Olive Oil in a daily diet will improve endothelial function.

Detailed Description
-----------------
Patients will be randomized to receive either placebo ROO (refined olive oil) or study solution EGCG-EVOO (EGCG enhanced extra-virgin olive oil) over the four month study period.

Official Title
-----------------
Effects of EGCG-Enhanced Extra Virgin Olive Oil on Endothelial Function

Conditions
-----------------
Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will be included in the study if they have an abnormal endothelial function study. This is defined at our institution as an RH-PAT index of less than 2. Patients will undergo two RH-PAT analyses and included abnormal values are obtained on either one or both tests. Only patients who provide written informed consent will be included. Exclusion Criteria: Patients with normal baseline endothelial function studies defined as RH-PAT index >2 will be excluded. Patients with uncontrolled hypertension >180/100 while on medication on initial evaluation will also be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Olive Oil A<br> | |
| Olive Oil B<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Supplementation with enhanced olive oil will improve endothelial function as assessed by the reactive hyperemia peripheral arterial tonometry (RH-PAT) in patients with coronary artery disease (CAD) risk factors and endothelial dysfunction |  | Baseline and post 4 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Supplementation of EGCG enhanced olive oil will reduce peripheral markers of endothelial dysfunction and inflammation, oxidative stress and inflammation |  | Baseline and post 4 month |
Use of Infrared Photomodulation for Hormonal Balance (Joovvin' for Hormonal Health)

Study Overview
=================
Brief Summary
-----------------
8-week pilot study looking at the impact of Joovv's infrared photo modulation product on male and female hormone levels.

Official Title
-----------------
Joovvin' for Hormonal Health

Conditions
-----------------
Testosterone Deficiency, Estrogen Deficiency

Intervention / Treatment
-----------------
* Device: Joovv Infrared Light Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: United States resident Exclusion Criteria: current Joovv or other photomodulation therapy user under medical supervision for medically treatable illness significant travel during study period use of birth control

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Interventional Model Description: Enrolled individuals will receive a Joovv solo for the 8 week study.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Study Arm<br>20 minutes Joovv Solo every day for 8 weeks. | Device: Joovv Infrared Light Device<br>* Joovv is the leading manufacturer of personal, in-home red light therapy devices<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Testosterone Change | in males, change from baseline to week 8 | baseline to week 8 | 
| change of thyroid-stimulating hormone (TSH) | in females change in estrogen and progesterone from baseline to week 8 | baseline to week 8 | 
| Self report general wellness | series of questions at baseline and week 8 on general wellness (modified Short Form-36) | baseline to week 8 |
Progression of Sub-Clinical Atherosclerosis

Study Overview
=================
Brief Summary
-----------------
To determine the rate of progression of sub-clinical cardiovascular disease as measured in carotid intimal medial thickness over a period of 8 to 10 years.

Detailed Description
-----------------
BACKGROUND: Strong associations exist between cardiovascular events and increased carotid artery wall intima-media thickness (IMT) as measured non-invasively by carotid ultrasound. Carotid IMT is accepted as a surrogate marker of sub-clinical cardiovascular disease.The study will determine the rate of progression of sub-clinical cardiovascular disease (change in IMT) over a period of 8 to 10 years. DESIGN NARRATIVE: The study will determine the rate of progression of sub-clinical cardiovascular disease (change in intimal medial thickness {IMT}) over a period of 8 to 10 years. Imaging and IMT measurements of approximately 2800 to 3000 members of the Framingham Offspring cohort having had baseline IMT measurements at their 1995-98 clinic visit will be repeated in 2005-2007. The principal aims of the project are to study the primary hypotheses that: 1. Interim exposure to traditional cardiovascular risk factors measured over 50 years is positively associated with the progression rate of carotid IMT. 2. Baseline carotid IMT and cumulative exposure to cardiovascular risk factors 20 years before the baseline visit are a better predictor of progression of sub-clinical disease after 8 to 10 years than the interim exposure to risk factors. 3. Novel risk factors such as C-reactive protein and homocysteine affect progression of carotid atherosclerosis more than traditional risk factors. This study will add a phenotypic marker of site-specific change in sub-clinical cardiovascular disease to the Framingham Study database. This complements ongoing research on the progression of sub-clinical cardiovascular disease and its associations with family history of premature cardiovascular events and genomic markers

Conditions
-----------------
Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Carotid Artery Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular Morbidity | Longitudinal follow-up of community based cohort | Longitudinal follow-up |
Randomized Evaluation of Vascular Entry Site and Radiation Exposure: REVERE Trial

Study Overview
=================
Brief Summary
-----------------
The study compares radiation exposure parameters between coronary angiography procedures performed by left wrist, right wrist or groin (femoral) procedure access site

Detailed Description
-----------------
Patients referred for coronary angiography will be randomized to either left radial, right radial or femoral arterial access sites, and the coronary angiogram will be performed in a standard fashion, including left ventriculography. Radiation exposure parameters including Air Kerma, Dose-area product, Fluoroscopy time and Operator radiation exposure will be recorded. Operator experience as well as demographic data will be recorded.

Official Title
-----------------
Randomized Evaluation of Vascular Entry Site and Radiation Exposure: REVERE Trial.

Conditions
-----------------
Exposure to Ionizing Radiation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients undergoing diagnostic coronary angiography Exclusion Criteria: non-availability of one or more of the three access sites History of coronary artery bypass graft surgery Need for percutaneous coronary intervention.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Femoral<br>Coronary angiography procedures performed using transfemoral access | |
| Left radial access<br>Coronary angiography procedures performed using left radial access site. | |
| Right radial Access<br>Coronary angiography procedures performed using Right radial access site. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Air Kerma | The investigators will measure Air Kerma (cumulative) at the end of the procedure of coronary angiography. | 1 day |
To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare PET measurements of fibrillar amyloid burden using [18F]AZD4694.

Official Title
-----------------
A Phase II, Open Label, Non-Randomized Study of [18F]AZD4694 to Compare PET Measurements of Fibrillar Amyloid Burden Obtained Using Difference Scanning Parameters, Reference Region Procedures and to Assess Test-retest Reliability in Patients With AD & HV

Conditions
-----------------
Alzheimer's Disease

Intervention / Treatment
-----------------
* Drug: [18F]AZD4694


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, of any race or/ethnicity ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician Exclusion Criteria: Significant recent (within 6 months) history of neurological (including stroke) or psychiatric disorder or substance abuse Participated in a PET study within the last 12 months Pregnancy or lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>[18F]4694 | Drug: [18F]AZD4694<br>* [18F]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PET Measurements |  | Day 1 and Day 7 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PET, Alzheimer's disease, diagnostic
Patient Centered Quality Reporting

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop a consumer friendly web-based interface between Nursing Home Compare (NHC) and an e-coaching/decision-aid tool (NHCPlus) and determine if use of NHCPlus facilitates and enhances access to and use of NHC.

Official Title
-----------------
Patient Centered Quality Reporting

Conditions
-----------------
Quality Report Cards

Intervention / Treatment
-----------------
* Other: NHCPlus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have been admitted as an inpatient into the departments of Medicine or Surgery at the UC Irvine Medical Center, and whose discharge plan is to a nursing home. Family members of these patients, if they are involved in the choice of nursing home, were also recruited to the study, either as joint decision makers with the patients or as proxy decision makers for the patient. Exclusion Criteria: Patients less than 50 years of age. Patients unable to use NHCPlus technology or participate in the nursing home choice decision (i.e. non-English speaking, severely visual or hearing impaired, dementia, or other debilitating illnesses) will be excluded unless they have a representative/proxy who will be involved in the decision to select the nursing home.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Intervention patients will receive access to NHCPlus when discharge to a nursing home from the hospital is expected. | Other: NHCPlus<br>* A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.<br>|
| No Intervention: Usual Care<br>Control patients will receive the usual care when discharge to a nursing home from the hospital is expected. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Use of Nursing Home Compare information | Patients (or their families) self report their knowledge and use of the information in Nursing Home Compare. | up to 9 days post discharge | 
| Quality Measures of chosen nursing home | Quality measures obtained from the Nursing Home Compare web based report card | up to 9 days post-discharge | 
| Distance between patient/family residence and the chosen nursing home. | Driving distance between the patient zip code and the chosen nursing home zip code using Google maps. | up to 9 days post-discharge | 
| Length of stay in hospital | Number of days between admission date and discharge date | between 1 and 68 days |
Human Single Neuron Recordings in Epilepsy Patients

Study Overview
=================
Brief Summary
-----------------
This study uses single neuron recordings in pre-surgical epilepsy patients to uncover the neural mechanisms underlying memory formation and retrieval. A secondary aim is to improve diagnostic tools to identify epileptogenic tissue.

Conditions
-----------------
Epilepsy, Memory

Intervention / Treatment
-----------------
* Diagnostic Test: Microwire electrodes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Interest in participation. Temporal lobe epilepsy that is clinically being investigated with implantations of depth electrodes as part of the pre-surgical epilepsy monitoring. Cognitive/language skills sufficient to follow experimental instruction and maintain focus on the experiment. Exclusion Criteria: Patient does not want to participate. Extra-temporal epilepsy, or electrode implantation strategy that does not allow the use of micro-macrowire electrodes. Cognitive/language skills insufficient to follow experimental instruction and maintain focus on the experiment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Microwire electrodes<br>Activity of individual neurons will be recorded via microwire contacts. These microwire electrodes do not interfere with the macrowire clinical recordings. | Diagnostic Test: Microwire electrodes<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Single unit recordings | Activity of individual neurons will be recorded via micro wire electrodes | 14 days (patient in hospital for this length of time) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intracranial electroencephalogram (iEEG) | Secondary outcome measures will be iEEG signals recorded with the macro electrodes, such as: Event-related potentials EEG power and phase of Theta oscillations EEG power and phase of Alpha/Beta oscillations EEG power and phase of Gamma oscillations EEG power of High Frequency Oscillations (>80 Hz) | 14 days (patient in hospital for this length of time) | 
| Behavioural response data | Laptop button presses and corresponding response times will be recorded in MATLAB and presentation file formats. This is acquired at patient's bedside during hospital admission. | 14 days (patient in hospital for this length of time) |
Hepatocyte Growth Factor and Cardiovascular Autonomic Function

Study Overview
=================
Brief Summary
-----------------
In this study, we tested the hypothesis that elevated HGF is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients not receiving insulin treatment.

Conditions
-----------------
Type-2 Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type-2 diabetes Exclusion Criteria: Type-1 diabetes
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Iodine Supplement Strategies Between Routine Iodine Supplementation and Selective Iodine Supplementation

Study Overview
=================
Brief Summary
-----------------
Pregnant women who attend at our antenatal clinic will random to 2 groups. First will receive routine iodine supplementation. The other will receive iodinated pill or only iron supplementation base on their urine iodine status.

Official Title
-----------------
The Study to Compare Iodine Supplement Strategies Between Routine Iodine Supplementation and Selective Iodine Supplementation

Conditions
-----------------
Pregnancy Related, Iodine Deficiency

Intervention / Treatment
-----------------
* Dietary Supplement: Triferdine
* Dietary Supplement: Triferdine/Ferli-6


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first visit for antenatal care in the first trimester singleton pregnancy delivered at Maharaj Nakorn Chiangmai Hospital Exclusion Criteria: thyroid disease which diagnosed before pregnancy or currently history of thyroid gland surgery or iodine ablation therapy received iodine supplement before pregnancy received any medication for thyroid disease treatment, within 6 weeks postpartum women or breast feeding period family history of thyroid disease having underlying disease or contraindication which cannot received iodine supplement loss follow-up or incomplete data.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Triferdine<br>Triferdine 1 tablet by mouth daily. Start after 1st trimester until delivery | Dietary Supplement: Triferdine<br>* Triferdine 1 tablet daily Start from 14 weeks of gestation until delivery<br>|
| Active Comparator: Triferdine/Ferli-6<br>Triferdine or ferli-6 1 tablet by mouth daily base on iodine status. The supplement will give after 1st trimester until delivery | Dietary Supplement: Triferdine/Ferli-6<br>* For the participants assigned to this group, urine iodine level will be checked first. For participants with normal urine iodine level, Ferli-6 1 tab daily will be given. For those with low urine iodine level, Triferdine 1 tab daily will be given. Medication will be started from 14 weeks of gestation until delivery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| iodine status | mean urine iodine | at delivery |
Preoperative Pain and POCD in Elderly Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether preoperative pain is the risk factor of POCD in elder patients.

Detailed Description
-----------------
Postoperative cognitive dysfunction (POCD) occurs mainly in aged patients. The mechanism of POCD is not clear yet and no effective therapy method. In the present study, we conducted a single-center observational prospective cohort trial in elder patients who undergoing hip joint replacement surgery with general anesthesia to test our hypothesis that preoperative chronic pain is one of the risk factors of POCD after major joint replacement surgery.

Official Title
-----------------
Preoperative Chronic Pain Increases the Risk of Early Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Hip Joint Replacement Surgery: a Prospective Observational Cohort Study

Conditions
-----------------
Postoperative Cognitive Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elder than 65 years old Speak Chinese Mandarin Those who will undergo major low limb surgery like hemiarthroplasty or total hip arthroplasty with general anesthesia. Signed the inform consent American Society of Anesthesiologists classification I to II Exclusion Criteria: Existing cerebral disease, or have a history of neurological and psychiatric disease including Alzheimer Disease, stroke, epilepsy and psychosis Existing cognitive impairment as evidenced by Mini-Mental State Examination scores below 24 Severe hearing or visual impairment Unwillingness to comply with the protocol or procedures Cannot communicate with Chinese Mandarin Serious pulmonary, heart , liver or renal insufficiency patients Had anesthesia or surgery within the past 30 days

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| POCD incidence 7 days (or before leaving hospital) after surgery | POCD incidence 7 days (or before leaving hospital) after surgery | 7 days (or before leaving hospital) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| POCD incidence 2 months after surgery | POCD incidence 2 months after surgery | 2 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postoperative Cognitive Dysfunction, elderly patients, Preoperative Pain